Free Trial
NASDAQ:ICCC

ImmuCell Q2 2025 Earnings Report

ImmuCell logo
$6.72 +0.19 (+2.91%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$6.72 0.00 (0.00%)
As of 08/14/2025 06:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Upcoming Event
Earnings Conference Call
ImmuCell Q2 2025
00:00 / 00:00
Live Transcript
Follow Audio

ImmuCell EPS Results

Actual EPS
$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ImmuCell Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ImmuCell Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Friday, August 15, 2025
Conference Call Time
9:00AM ET

ImmuCell Earnings Headlines

ImmuCell Corporation: ImmuCell Announces Bank Debt Refinancing
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
ImmuCell Refinances Debt with Maine Community Bank
ImmuCell Announces Bank Debt Refinancing
See More ImmuCell Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImmuCell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmuCell and other key companies, straight to your email.

About ImmuCell

ImmuCell (NASDAQ:ICCC), an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

View ImmuCell Profile

More Earnings Resources from MarketBeat